RESUMEN
OBJECTIVE: To assess the prognosis and outcome of patients with isolated carotid vasculitis. METHODS: We performed a retrospective multicenter study of 36 patients (median age at diagnosis was 37 [IQR 27-45] years and 11 [31 %] patients were men) with initial presentation as isolated carotid vasculitis. Study endpoints included vascular complications, relapses, and progression to large vessel vasculitis (i.e. Giant cell arteritis or Takayasu). RESULTS: The most frequent involvement was the left internal carotid artery (39 %), and 81 % had stenosis. After a median follow-up of 32 months [IQR 12-96], 21 (58 %) patients had a vascular event, including 31 % of new onset vascular lesions and 25 % of stroke/transient ischemic attack. Patients with stroke had less carotidynia at diagnosis (33 % vs 74 %, p = 0.046), higher significant carotid stenosis (i.e. > 50 %) (89 % vs. 30 %, p = 0.026) and higher severe carotid stenosis (i.e. >70 %) (67 % vs 19 %, p = 0.012), compared to those without stroke. Twenty (52 %) patients experienced relapses. High CRP at diagnosis was associated with relapses (p = 0.022). At the end of follow-up, 21 (58 %) patients were classified as having Takayasu arteritis, 13 (36 %) as isolated carotid vasculitis, and two (6 %) as giant cell arteritis. CONCLUSION: Carotid vasculitis may occur as a topographically limited lesion and is associated with significant rate of vascular complications.
Asunto(s)
Arteritis de Células Gigantes , Humanos , Masculino , Femenino , Pronóstico , Persona de Mediana Edad , Estudios Retrospectivos , Adulto , Arteritis de Células Gigantes/diagnóstico , Arteritis de Takayasu/diagnóstico , Recurrencia , Vasculitis/diagnóstico , Estudios de Seguimiento , Accidente Cerebrovascular/etiología , Accidente Cerebrovascular/diagnóstico , Estenosis Carotídea/diagnóstico , Progresión de la EnfermedadRESUMEN
Uveitis in Behçet's disease (BD) is frequent (40% of cases) and is a major cause of morbidity. The age of onset of uveitis is between 20 and 30 years. Ocular involvement includes anterior, posterior or panuveitis. It is non-granulomatous. Uveitis may be the first sign of the disease in 20% of cases or it may appear 2 or 3 years after the first symptoms. Panuveitis is the most common presentation and is more commonly found in men. Bilateralisation usually occurs on average 2 years after the first symptoms. The estimated risk of blindness at 5 years is 10-15%. BD uveitis has several ophthalmological features that distinguish it from other uveitis. The main goals in the management of patients are the rapid resolution of intraocular inflammation, prevention of recurrent attacks, achievement of complete remission, and preservation of vision. Biologic therapies have changed the management of intraocular inflammation. The aim of this review is to provide an update previous article by our team on pathogenesis, diagnostic approaches, identification of factors associated with relapse and the therapeutic strategy of BD uveitis.
RESUMEN
Neurosarcoidosis (NS) is a rare but severe form of sarcoidosis. NS is associated with significant morbidity and mortality. Mortality is about 10% at 10 years with more than 30% of patients who have a significant disability. The most frequent features are cranial neuropathy (the facial and optic nerve most commonly affected), cranial parenchymal lesions, meningitis, spinal corn abnormalities (20-30%) and more rarely peripheral neuropathy (approximately 10-15%). The challenge of diagnosis is to eliminate other diagnoses. Atypical presentations should make to discuss the need for cerebral biopsy in order to highlight the presence of granulomatous lesions while eliminating alternative diagnosis. Therapeutic management is based on corticosteroid therapy and immunomodulators. There are no comparative prospective study to allow us to define the first-line immunosuppressive treatment and the therapeutic strategy in refractory patients. Conventional immunosuppressants such as methotrexate, mycophenolate mofetil and cyclophosphamide are commonly used. Data on the efficacy of anti-TNFα (including infliximab) in refractory and/or severe forms are increasing during the last ten years. Additional data is necessary to assess their interest in first line in patients with severe involvement and a significant risk of relapse.
Asunto(s)
Enfermedades del Sistema Nervioso Central , Sarcoidosis , Humanos , Estudios Prospectivos , Inmunosupresores/uso terapéutico , Enfermedades del Sistema Nervioso Central/complicaciones , Enfermedades del Sistema Nervioso Central/diagnóstico , Enfermedades del Sistema Nervioso Central/terapia , Sarcoidosis/complicaciones , Sarcoidosis/diagnóstico , Sarcoidosis/terapiaRESUMEN
Sarcoidosis is a systemic granulomatous disease characterized by pulmonary involvement in most patients and more rarely by extrapulmonary involvement such as ocular, skin, salivary, lymph nodes and joints damages. Neurological and cardiac involvements are uncommon but are associated with increased morbidity and mortality. Cardiac sarcoidosis affects 5 to 20% of patients depending on the studies and autopsy studies even report cardiac involvement in 25% of sarcoidosis patients. This review aims to summarise main data on the diagnostic value of the different imaging techniques in cardiac sarcoidosis and to also detail the management of these patients who require a multidisciplinary approach.
Asunto(s)
Miocarditis , Sarcoidosis , Granuloma/complicaciones , Humanos , Ganglios Linfáticos/patología , Miocarditis/complicaciones , Pronóstico , Sarcoidosis/complicaciones , Sarcoidosis/diagnóstico , Sarcoidosis/terapiaRESUMEN
OBJECTIVE: Our aim was to compare transcriptome and phenotype profiles of CD4+ T cells and CD19+ B cells in patients with Takayasu arteritis (TAK), patients with giant cell arteritis (GCA), and healthy donors. METHODS: Gene expression analyses, flow cytometry immunophenotyping, T cell receptor (TCR) gene sequencing, and functional assessments of cells from peripheral blood and arterial lesions from TAK patients, GCA patients, and healthy donors were performed. RESULTS: Among the most significantly dysregulated genes in CD4+ T cells of TAK patients compared to GCA patients (n = 720 genes) and in CD4+ T cells of TAK patients compared to healthy donors (n = 1,447 genes), we identified a follicular helper T (Tfh) cell signature, which included CXCR5, CCR6, and CCL20 genes, that was transcriptionally up-regulated in TAK patients. Phenotypically, there was an increase in CD4+CXCR5+CCR6+CXCR3- Tfh17 cells in TAK patients that was associated with a significant enrichment of CD19+ B cell activation. Functionally, Tfh cells helped B cells to proliferate, differentiate into memory cells, and secrete IgG antibodies. Maturation of B cells was inhibited by JAK inhibitors. Locally, in areas of arterial inflammation, we found a higher proportion of tertiary lymphoid structures comprised CD4+, CXCR5+, programmed death 1+, and CD20+ cells in TAK patients compared to GCA patients. CD4+CXCR5+ T cells in the aortas of TAK patients had an oligoclonal α/ß TCR repertoire. CONCLUSION: We established the presence of a specific Tfh cell signature in both circulating and aorta-infiltrating CD4+ T cells from TAK patients. The cooperation of Tfh cells and B cells might be critical in the occurrence of vascular inflammation in patients with TAK.
Asunto(s)
Linfocitos B/inmunología , Arteritis de Células Gigantes/inmunología , Células T Auxiliares Foliculares/inmunología , Arteritis de Takayasu/inmunología , Adulto , Anciano , Anciano de 80 o más Años , Antígenos CD19/metabolismo , Antígenos CD20/metabolismo , Aorta , Linfocitos B/efectos de los fármacos , Linfocitos B/metabolismo , Linfocitos T CD4-Positivos/efectos de los fármacos , Linfocitos T CD4-Positivos/inmunología , Linfocitos T CD4-Positivos/metabolismo , Proliferación Celular , Femenino , Perfilación de la Expresión Génica , Arteritis de Células Gigantes/genética , Humanos , Inmunoglobulina G/metabolismo , Memoria Inmunológica , Inmunofenotipificación , Inhibidores de las Cinasas Janus/farmacología , Masculino , Persona de Mediana Edad , Nitrilos , Receptor de Muerte Celular Programada 1/metabolismo , Pirazoles/farmacología , Pirimidinas , Receptores de Antígenos de Linfocitos T alfa-beta/genética , Receptores CXCR5/metabolismo , Células T Auxiliares Foliculares/efectos de los fármacos , Células T Auxiliares Foliculares/metabolismo , Arteritis de Takayasu/genética , Estructuras Linfoides Terciarias/inmunología , Estructuras Linfoides Terciarias/metabolismo , Estructuras Linfoides Terciarias/patología , TranscriptomaRESUMEN
OBJECTIVE: To describe the outcome and tolerance in patients treated with anti-TNFα in severe and refractory major vessel disease in Behçet's disease (BD). METHODS: A multicenter study evaluating 18 refractory BD patients with major vessel involvement [pulmonary artery (nâ¯=â¯4), aorta (nâ¯=â¯4) or peripheral artery aneurysm (nâ¯=â¯1) and/or pulmonary artery (nâ¯=â¯7), inferior vena cava (nâ¯=â¯5), or intra-cardiac (nâ¯=â¯3) thrombosis or Budd Chiari Syndrome (nâ¯=â¯2)] treated with anti-TNFα agents. RESULTS: Vascular remission was achieved in 16 (89%) patients. The 9â¯months risk of relapse was significantly higher with conventional immunosuppressants used prior anti-TNFα agents as compared to anti-TNFα therapy [ORâ¯=â¯8.7 (1.42-62.6), pâ¯=â¯0.03]. The median daily dose of corticosteroids significantly decreased at 12â¯months. Side effects included infection (nâ¯=â¯4) and pulmonary edema (nâ¯=â¯1). CONCLUSION: TNFα-antagonists are safe and might be associated with a decreased risk of relapse at 9â¯months compared to conventional immunosuppressants in BD patients with major vessels disease.
Asunto(s)
Adalimumab/uso terapéutico , Antirreumáticos/uso terapéutico , Síndrome de Behçet/tratamiento farmacológico , Infliximab/uso terapéutico , Trombosis/fisiopatología , Adulto , Enfermedades de la Aorta/etiología , Enfermedades de la Aorta/fisiopatología , Síndrome de Behçet/complicaciones , Síndrome de Behçet/fisiopatología , Síndrome de Budd-Chiari/etiología , Síndrome de Budd-Chiari/fisiopatología , Femenino , Cardiopatías/etiología , Cardiopatías/fisiopatología , Humanos , Inmunosupresores/uso terapéutico , Infecciones , Modelos Logísticos , Masculino , Persona de Mediana Edad , Arteria Pulmonar/fisiopatología , Edema Pulmonar , Recurrencia , Inducción de Remisión , Estudios Retrospectivos , Índice de Severidad de la Enfermedad , Trombosis/etiología , Factor de Necrosis Tumoral alfa/antagonistas & inhibidores , Enfermedades Vasculares/etiología , Enfermedades Vasculares/fisiopatología , Vena Cava Inferior/fisiopatología , Adulto JovenRESUMEN
BACKGROUND: Mammalian target of rapamycin complex 1 (mTORC 1) drives the proinflammatory expansion of T helper (TH) type 1, TH17â¯cells and controls fibroblast proliferation, typical features of large vessel vasculitis (LVV) pathogenesis. Molecular pathways involved in arterial lesions of LVV are unknown. METHODS: We evaluate mTORC pathway activation in vascular aorta lesions and in T cell homeostasis of patients with LVV. RESULTS: Proliferation of both endothelial cells and vascular smooth-muscle cells was shown in vascular lesions in LVV. The vascular endothelium of proliferating aorta vessels from patients with LVV showed indications of activation of the mTORC1 pathway (S6RP phosphorylation). In cultured vascular endothelial cells, sera from patients with LVV stimulated mTORC1 through the phosphorylation of S6RP. mTORC1 activation was found also in Th1 and Th17â¯cells both systemically and in inflamed vessels. Patients with LVV exhibited a diminished S6RP phosphorylation in Tregs. Inhibition of mTORC1 pathway with rapamycin, increase Tregs and decrease effector CD4+IFNγ+, CD4+IL17+ and CD4+IL21+ T cells in patients with LVV. CONCLUSIONS: We provided evidence that mTORC1 pathway has a central role in driving T cell inflammation and vascular lesions in LVV. Targeting mTORC pathway may represent a new therapeutic option in patients with LVV.
Asunto(s)
Células Endoteliales/inmunología , Diana Mecanicista del Complejo 1 de la Rapamicina/genética , Miocitos del Músculo Liso/inmunología , Linfocitos T Reguladores/inmunología , Serina-Treonina Quinasas TOR/genética , Vasculitis/genética , Adulto , Anciano , Aorta/efectos de los fármacos , Aorta/inmunología , Aorta/patología , Estudios de Casos y Controles , Proliferación Celular , Células Endoteliales/efectos de los fármacos , Células Endoteliales/patología , Femenino , Regulación de la Expresión Génica , Humanos , Interferón gamma/genética , Interferón gamma/inmunología , Interleucina-17/genética , Interleucina-17/inmunología , Interleucinas/genética , Interleucinas/inmunología , Masculino , Diana Mecanicista del Complejo 1 de la Rapamicina/antagonistas & inhibidores , Diana Mecanicista del Complejo 1 de la Rapamicina/inmunología , Persona de Mediana Edad , Miocitos del Músculo Liso/efectos de los fármacos , Miocitos del Músculo Liso/patología , Fosforilación/efectos de los fármacos , Cultivo Primario de Células , Transducción de Señal , Sirolimus/farmacología , Linfocitos T Reguladores/efectos de los fármacos , Linfocitos T Reguladores/patología , Serina-Treonina Quinasas TOR/antagonistas & inhibidores , Serina-Treonina Quinasas TOR/inmunología , Células TH1/efectos de los fármacos , Células TH1/inmunología , Células TH1/patología , Células Th17/efectos de los fármacos , Células Th17/inmunología , Células Th17/patología , Vasculitis/inmunología , Vasculitis/patologíaRESUMEN
Ocular disease in Behçet's disease is frequent and may be associated with a poor functional prognosis. Uveitis is the most common ocular manifestation in Behçet's disease and represents a diagnostic criterion of the disease. The ocular involvement is inaugural of the disease in 20% of the cases or may develop 2 to 3 years after the beginning of the extraocular signs. The risk of blindness at 5 years is in the order of 15 to 25%, mainly due to macular involvement or retinal vasculitis. Uveitis may be anterior, intermediate, posterior or panuveitis. Anterior uveitis is rarely isolated and is frequently accompanied by posterior involvement. Anterior uveitis is always non granulomatous, sometimes associated with hypopion. Posterior involvement may include the presence of hyalitis, retinal vasculitis, mainly venous and often occlusive, macular edema, and/or foci of necrotizing retinitis. Behçet's disease is a chronic disorder, characterized by a relapsing and remitting course. Male patients with younger age at onset and severe lesions at presentation are at higher risk of severe visual loss over time. The main goals in the management of patients with Behçet's disease-associated uveitis are rapid suppression of intraocular inflammation, preservation of vision, and prevention of recurrences. The treatment is based on the use of systemic glucocorticosteroids and immunosuppressive agents. Posterior segment involvement requires the use of corticosteroids and immunosuppressants, primarily azathioprine. This treatment does not appear to be sufficient for severe uveitis with reduced visual acuity or retinal vasculitis that requires anti-TNF α or interferon α. Therapeutic strategies such as TNF-alpha blockers have dramatically improved the visual prognosis of patients with intraocular inflammation related to this chronic and potentially blinding condition.
Asunto(s)
Síndrome de Behçet/complicaciones , Oftalmopatías/etiología , Síndrome de Behçet/diagnóstico , Síndrome de Behçet/epidemiología , Síndrome de Behçet/terapia , Diagnóstico Diferencial , Técnicas de Diagnóstico Oftalmológico , Oftalmopatías/diagnóstico , Oftalmopatías/epidemiología , Oftalmopatías/terapia , Humanos , Inmunosupresores/uso terapéutico , Factor de Necrosis Tumoral alfa/antagonistas & inhibidores , Factor de Necrosis Tumoral alfa/inmunología , Trastornos de la Visión/diagnóstico , Trastornos de la Visión/epidemiología , Trastornos de la Visión/etiología , Trastornos de la Visión/terapiaRESUMEN
BACKGROUND: The economic impact of extrahepatic manifestations of hepatitis C virus (HCV) infection remains unknown for France. AIM: To estimate the prevalence of extrahepatic manifestations of HCV and the direct medical costs associated with them. METHODS: Estimates of 13 extrahepatic manifestations prevalence were obtained from (1) a retrospective data analysis of HCV-infected patients in a specialised centre and the baseline prevalence in the general French population and (2) an international systematic review. Per-patient-per-year costs to treat these manifestations were obtained from the literature, national databases or expert opinion. The impact of achieving HCV cure after anti-viral therapy was applied to the French healthcare costs. RESULTS: Using approach (1), increased prevalence rates in HCV patients compared to the general population were observed for most extrahepatic manifestations. The mean per-patient-per-year cost of these manifestations in the tertiary centre was 3296 [95% CI 1829; 5540]. In France, HCV-extrahepatic manifestations amounted to a total cost of 215 million (M) per year [144; 299]. Using approach (2), the mean per-patient-per-year cost was estimated to be 1117 . The estimated total cost reduction in France associated with HCV cure was 13.9 M for diabetes, 8.6 M for cryoglobulinemia vasculitis, 6.7 M for myocardial infarction, 2.4 M for end-stage renal disease and 1.4 M for stroke. CONCLUSION: Extrahepatic manifestations of HCV infection substantially add to the overall economic burden of the disease in France. HCV cure after anti-viral therapy is expected to significantly reduce the total costs of managing these manifestations in France.
Asunto(s)
Costos de la Atención en Salud , Hepacivirus/aislamiento & purificación , Hepatitis C/complicaciones , Crioglobulinemia , Francia/epidemiología , Hepatitis C/tratamiento farmacológico , Hepatitis C/economía , Humanos , Prevalencia , Estudios RetrospectivosRESUMEN
INTRODUCTION: The efficacy of anti-TNFα agents has been recently evaluated in many studies in Behçet's disease (BD), particularly in ocular and life-threatening manifestations such as neurological and vascular disease. Areas covered: The following article aims to summarize the currently available efficacy and safety data of anti-TNFα agents in BD. Expert opinion: Most studies have shown dramatic and rapid efficacy with anti-TNFα agents on the main BD-associated issues including posterior uveitis, gastro-intestinal and neurological complications as well as major vessel disease. Experts in the field do recommend the use of anti-TNF agents (either infliximab or adalimumab) as a first-line therapy in severe posterior uveitis in BD and now use anti-TNFα treatment in BD-associated life threatening manifestations. However, data is mainly based on retrospective cohorts or open-label prospective studies. Controlled studies (versus conventional immunosuppressants such as azathioprine and cyclophosphamide) are warranted to properly evaluate their efficacy as first line therapeutic in life-threatening manifestations of BD.
Asunto(s)
Anticuerpos Monoclonales/uso terapéutico , Síndrome de Behçet/tratamiento farmacológico , Inhibidores del Factor de Necrosis Tumoral , Adalimumab/uso terapéutico , Anticuerpos Monoclonales/inmunología , Antimetabolitos Antineoplásicos/uso terapéutico , Azatioprina/uso terapéutico , Síndrome de Behçet/metabolismo , Síndrome de Behçet/patología , Humanos , Infliximab/uso terapéutico , Factores de Necrosis Tumoral/inmunología , Factores de Necrosis Tumoral/metabolismoRESUMEN
Giant cell arteritis (GCA) and Takayasu's arteritis (TA) are large vessel vasculitis (LVV) and aortic involvement is not uncommon in Behcet's disease (BD) and relapsing polychondritis (RP). Glucocorticosteroids are the mainstay of therapy in LVV. However, a significant proportion of patients have glucocorticoid dependance, serious side effects or refractory disease to steroids and other immunosuppressive treatments such as cyclophosphamide, azathioprine, mycophenolate mofetil and methotrexate. Recent advances in the understanding of the pathogenesis have resulted in the use of biological agents in patients with LVV. Anti-tumor necrosis factor-α drugs seem effective in patients with refractory Takayasu arteritis and vascular BD but have failed to do so in giant cell arteritis. Preliminary reports on the use of the anti-IL6-receptor antibody (tocilizumab), in LVV have been encouraging. The development of new biologic targeted therapies will probably open a promising future for patients with LVV.
Asunto(s)
Síndrome de Behçet/tratamiento farmacológico , Terapia Biológica/métodos , Arteritis de Células Gigantes/tratamiento farmacológico , Inmunosupresores/uso terapéutico , Policondritis Recurrente/tratamiento farmacológico , Arteritis de Takayasu/tratamiento farmacológico , HumanosRESUMEN
The arterial lesions affect about 10% of patients with Behçet's disease (BD). Aortic inflammatory involvement includes predominantly aortic aneurysmal lesions affecting most often the abdominal aorta. They account for the severity of the disease and are a leading cause of death when they hit the aorta or pulmonary arteries. Within the arterial lesions of BD, aortic involvement is, with femoral lesions, the most common site involved (18-28% of patients with vascular disease). Unlike other large vessels vasculitis (i.e. giant cell arteritis and Takayasu's arteritis) diffuse aortitis is observed in less than 5% of patients with BD. Aortic lesions of BD may be asymptomatic (systematic imaging or occasionally associated with other vascular event) or be revealed by the occurrence of abdominal, thoracic or lumbar pain, or an aortic valve insufficiency. Fever is frequently associated. Increase in acute phase reactants is common in these patients. Histological analysis may show infiltration by lymphocytes, neutrophils and plasma cells in the media and adventitia and a proliferation of the vasa vasorum in the media as well as a fibroblastic proliferation. In the later phase, a fibrous thickening of the media and adventitia is observed as well as a proliferation and thickening of the vasa vasorum. The therapeutic management should always include a medical treatment for the control of inflammation (corticosteroids, immunosuppressive drugs and/or biotherapy) and often an endovascular or surgical treatment if the aneurysm is threatening. The choice between endovascular or surgical treatment is considered case by case, depending on the experience of the team, anatomical conditions and of the clinical presentation. In this review, we provide a detailed and updated review of the literature to describe the aortic inflammatory damage associated with Behçet's disease.
Asunto(s)
Aortitis/complicaciones , Síndrome de Behçet/complicaciones , Aneurisma de la Aorta/diagnóstico por imagen , Aneurisma de la Aorta/etiología , Aneurisma de la Aorta/terapia , Aortitis/diagnóstico por imagen , Aortitis/terapia , Síndrome de Behçet/diagnóstico por imagen , Síndrome de Behçet/terapia , Terapia Biológica/métodos , Arteritis de Células Gigantes/diagnóstico por imagen , Arteritis de Células Gigantes/etiología , Arteritis de Células Gigantes/terapia , Humanos , Inmunosupresores/uso terapéutico , Arteritis de Takayasu/diagnóstico por imagen , Arteritis de Takayasu/etiología , Arteritis de Takayasu/terapiaAsunto(s)
Hepatitis C Crónica/complicaciones , Enfermedades Cardiovasculares/virología , Disfunción Cognitiva/virología , Crioglobulinemia/virología , Diabetes Mellitus/virología , Hepacivirus/fisiología , Hepatitis C Crónica/diagnóstico , Humanos , Fenotipo , Insuficiencia Renal/virología , Factores de Riesgo , Accidente Cerebrovascular/virología , Vasculitis/virologíaRESUMEN
OBJECTIVE: Takayasu arteritis (TAK) is a large-vessel vasculitis that induces damage to the aorta and its branches. Glucocorticoids remain the gold standard of therapy for TAK. The nature of the T cells driving vascular inflammation and the effects of glucocorticoids on the systemic components of TAK are not understood. The aim of this study was to analyze T cell homeostasis and cytokine production in peripheral blood and inflammatory lesions of the aorta in patients with TAK. METHODS: T cell homeostasis and cytokine production in peripheral blood and inflammatory lesions of the aorta were analyzed using Luminex analysis, flow cytometry, and immunohistochemical analysis. The study included 41 patients fulfilling the American College of Rheumatology 1990 criteria for the classification of TAK (17 patients with active TAK and 24 patients with disease in remission), 30 patients with giant cell arteritis and 39 patients with Behçet's disease (disease controls), and 20 age- and sex-matched healthy control subjects. RESULTS: We observed a marked increase in the expression of Th1 and Th17 cells, which correlated with TAK disease activity. The addition of serum from patients with active TAK to sorted CD4+ T cells from healthy donors in culture medium induced significant production of interferon-γ (IFNγ) and interleukin-17A (IL-17A). We demonstrated the presence of IFNγ-, IL-6-, and IL-17A-producing T cells in vascular inflammatory infiltrates in patients with TAK. Corticosteroid therapy was associated with decreased levels of circulating Th1 cytokines in corticosteroid-treated patients with TAK compared with steroid-free patients with TAK (for IL-2, mean ± SD 5,079 ± 5,300 versus 7,359 ± 3,197 pg/ml; for IFNγ, 2,592 ± 3,072 versus 8,393 ± 3,392 pg/ml; for tumor necrosis factor α, 847 ± 724 versus 1,491 ± 392 pg/ml). However, glucocorticoids had essentially no effect on the frequency of Th17 cytokines (IL-1 receptor, IL-17, and IL-23). CONCLUSION: The Th17 and Th1 pathways contribute to the systemic and vascular manifestations of TAK. Glucocorticoid treatment suppresses Th1 cytokines but spares Th17 cytokines in patients with TAK.